Obicetrapib
Sponsors
NewAmsterdam Pharma B.V., NewAmsterdam Pharma
Conditions
Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)Atherosclerotic Cardiovascular DiseaseDyslipidemiaDyslipidemiasEarly Alzheimer's DiseaseFamilial HypercholesterolemiaGenetic Disease, InbornHealthy
Phase 1
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
Active, not recruitingNCT05972278
Start: 2023-12-01End: 2024-10-14Updated: 2024-09-19
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
CompletedNCT06048302
Start: 2023-11-30End: 2024-03-19Updated: 2024-09-19
A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin
CompletedNCT06081166
Start: 2023-11-11End: 2024-01-22Updated: 2025-05-22
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
CompletedNCT06250205
Start: 2024-02-05End: 2024-04-26Updated: 2024-09-19
Phase 2
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
CompletedNCT04753606
Start: 2021-02-18End: 2021-08-30Updated: 2024-07-12
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
CompletedNCT05161715
Start: 2022-01-12End: 2023-06-01Updated: 2025-01-29
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
CompletedNCT05266586
Start: 2022-03-09End: 2022-09-08Updated: 2024-07-03
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
CompletedNCT05421078
Start: 2022-06-27End: 2023-04-21Updated: 2024-10-29
Phase 3
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
CompletedNCT05142722
Start: 2021-12-15End: 2024-09-26Updated: 2025-09-19
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
Active, not recruitingNCT05202509
Start: 2022-02-07End: 2026-11-30Updated: 2024-06-04
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
CompletedNCT05425745
Start: 2022-07-25End: 2024-05-28Updated: 2025-06-11
Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
Active, not recruitingCTIS2023-507795-51-00
Start: 2022-05-17Target: 4094Updated: 2026-01-27
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS trial)
Not yet recruitingCTIS2025-521936-12-00
Target: 118Updated: 2026-04-01